Biomedical subjects
Publications and source records attributed to K Lund-Olesen.
The etiology of multiple sclerosis is still unknown, despite intensive research for many decades. It has, however, been shown recently that defects in the genes may be responsible for conditions such as amyotrophic lateral sclerosis (1).
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
It is suggested that chronic fatigue syndrome/fibromyalgia is caused by virus injury to the calcium channels leading to larger quantities than usual of calcium ions entering the striated muscle cells. Should this be true, then treatment with a calcium antagonist (CA) may possibly be of value.
Explore the source record for details and available documents.
During the period 1971-78, 133 intrathecal injections of orgotein or superoxide dismutase have been given, mostly to patients with multiple sclerosis. Evaluation of the effect was deficient but the impression was that of improvement and 45% of the 58 patients with multiple sclerosis requested further intrathecal injections. In one case, intrathecal injections had a good effect against allergic headaches after myelography. Determination of orgotein in samples of cerebrospinal fluid from 16 patients with multiple sclerosis gave remarkable results in that the content of orgotein was significantly lower than the level reported by other investigators.
Intra-articular efficacy and long-term safety of orgotein, the drug version of Cu-Zn superoxide dismutase, were explored in a 24-week double-blind, placebo-controlled trial in patients with active osteoarthritis (ARA criteria) of the knee joint. Each patient received twelve intra-articular injections at biweekly intervals of orgotein (2 mg) or placebo dissolved in about 2 ml saline injection, USP. No other antiinflammatory medications were permitted. By the end of the trial, significant efficacy of orgotein over placebo had been reached in the parameters of pain, functional improvement and evaluation of status both by physician and patient. With the orgotein dose regimen used, improvement of disease activity versus time progressed with a fairly constant slope. In the placebo group a surprisingly large initial response was observed which lasted as long as 12 weeks in some instances before subsiding.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.